Neuronetics to Present at the William Blair 40th Annual Growth Stock Conference

Rhea-AI Summary

MALVERN, Pa., June 4, 2020 - Neuronetics, a medical technology company focused on psychiatric disorders, will present at the William Blair 40th Annual Growth Stock Conference on June 11, 2020, at 11:40 a.m. ET. The presentation will be accessible via a live audio webcast on their investor relations page. Neuronetics’ flagship product, the NeuroStar® Advanced Therapy System, uses transcranial magnetic stimulation to treat major depressive disorder in adult patients. The webcast will be archived for 90 days following the event.

MALVERN, Pa., June 04, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the management team will participate in the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020. The Company is scheduled to present at the conference at 11:40 a.m. Eastern Time (10:40 a.m. Central Time) the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.  NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Investor Contact:

Mark R. Klausner
Westwicke Partners
443-213-0501
ir@neuronetics.com

Media Contact:

Chelsey Manko
Vault Communications
610-455-2778
cmanko@vaultcommunications.com

FAQ

When is Neuronetics scheduled to present at the William Blair Conference?

Neuronetics will present at the William Blair 40th Annual Growth Stock Conference on June 11, 2020, at 11:40 a.m. Eastern Time.

How can I watch the Neuronetics presentation at the conference?

The Neuronetics presentation will be available via a live audio webcast on their investor relations page.

What is the NeuroStar® Advanced Therapy System?

The NeuroStar® Advanced Therapy System is a non-invasive treatment using transcranial magnetic stimulation for patients with major depressive disorder.

Is the NeuroStar system FDA approved?

Yes, the NeuroStar system is cleared by the FDA for the treatment of major depressive disorder in adults.

Where else is NeuroStar available apart from the U.S.?

NeuroStar is also available in Japan, listed under the national health insurance.